Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J Frontier CoFRA:R0L 58 Debt-to-EBITDA is 6.94 as of Feb. 2026, which is 864% above its 10-year median of 0.72. GuruFocus rates FRA:R0L with a GF Score™ of 58/100 and a GF Value™ of €9.25 (Modestly Overvalued). The stock has 11 warning signs investors should review. Among 481 Healthcare Providers & Services companies, J Frontier Co ranks worse than 94.59% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for J Frontier Co's Debt-to-EBITDA or its related term are showing as below:
FRA:R0L'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.22 Med: 0.72 Max: 14.96
Current: 14.96
During the past 8 years, the highest Debt-to-EBITDA Ratio of J Frontier Co was 14.96. The lowest was -4.22. And the median was 0.72.
FRA:R0L's Debt-to-EBITDA is ranked worse than 94.59% of 481
companies
in the Healthcare Providers & Services industry
Industry Median: 2.19
vs FRA:R0L: 14.96
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
J Frontier Co Debt-to-EBITDA Related Terms
J Frontier Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for J Frontier Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
J Frontier Co Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, J Frontier Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J Frontier Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, J Frontier Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where J Frontier Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Feb. 2026) EBITDA data.
J Frontier Co (FRA:R0L) has a Debt-to-EBITDA of 6.94 as of Feb. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on J Frontier Co. This is 864% above median its historical median of 0.72. According to the industry distribution chart, J Frontier Co ranks #455 out of 481 companies in the Healthcare Providers & Services industry, placing it in the top 94.6%.
Is J Frontier Co's Debt-to-EBITDA too high?
J Frontier Co's current Debt-to-EBITDA of 6.94 is 864% above median its 10-year median of 0.72. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. J Frontier Co's value of 6.94 is 216.9% above this industry median. Based on the distribution chart, J Frontier Co ranks #455 out of 481 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, J Frontier Co has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does J Frontier Co's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, J Frontier Co ranks #455 out of 481 companies for Debt-to-EBITDA. This places J Frontier Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. J Frontier Co's value of 6.94 is 216.9% above this benchmark. While the company's 10-year median is 0.72 vs. the industry median of 2.19, J Frontier Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 481 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. J Frontier Co's current Debt-to-EBITDA of 6.94 is 216.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on J Frontier Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J Frontier Co's current Debt-to-EBITDA is 6.94, which is 864% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J Frontier Co stock overvalued right now?
Based on GuruFocus' analysis, J Frontier Co (FRA:R0L) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.25, compared to a current price of €10.40 — trading 12.4% above its estimated fair value. The current Debt-to-EBITDA is 6.94, which is 864% above median its 10-year median of 0.72 and 216.9% above the Healthcare Providers & Services industry median of 2.19. J Frontier Co's overall GF Score™ is 58/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For J Frontier Co (FRA:R0L), the current Debt-to-EBITDA is 6.94 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J Frontier Co (FRA:R0L) Overvalued in 2026?
Based on GuruFocus' analysis, J Frontier Co stock appears to be overvalued.
The current stock price of €10.40 is trading 12.4% above its estimated GF Value™ of €9.25.
GuruFocus considers J Frontier Co to be Modestly Overvalued.
Key valuation signals for FRA:R0L:
Debt-to-EBITDA: 6.94 (864% above median its 10-year median of 0.72)
GF Value™: €9.25 vs. price of €10.40 (12.4% above fair value)
Industry Position: 216.9% above the Healthcare Providers & Services median (#455 of 481)
No single metric tells the full story. See the FRA:R0L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R0L has been successfully added to your 
